Voyager Therapeutics (NASDAQ:VYGR) Raised to Buy at StockNews.com

Voyager Therapeutics (NASDAQ:VYGR) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Monday.

Several other analysts have also weighed in on the stock. Wedbush decreased their target price on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $14.00 price objective on shares of Voyager Therapeutics in a report on Thursday, November 14th. Leerink Partners assumed coverage on Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price objective on the stock. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 14th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $17.00.

Voyager Therapeutics Trading Down 2.1 %

Shares of VYGR stock opened at $5.27 on Monday. Voyager Therapeutics has a 12 month low of $5.19 and a 12 month high of $11.72. The company has a market capitalization of $287.90 million, a P/E ratio of 7.42 and a beta of 0.89. The stock has a 50 day moving average of $6.59 and a two-hundred day moving average of $7.45.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. The business had revenue of $24.63 million during the quarter, compared to analyst estimates of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same period in the prior year, the company posted ($0.59) earnings per share. Sell-side analysts predict that Voyager Therapeutics will post -1.12 earnings per share for the current fiscal year.

Insider Buying and Selling at Voyager Therapeutics

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the sale, the insider now owns 86,001 shares of the company’s stock, valued at $500,525.82. This represents a 6.52 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 4.53% of the company’s stock.

Hedge Funds Weigh In On Voyager Therapeutics

A number of large investors have recently modified their holdings of VYGR. Armistice Capital LLC raised its position in Voyager Therapeutics by 11.3% in the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $41,132,000 after purchasing an additional 528,000 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Voyager Therapeutics by 27.8% during the first quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock worth $30,087,000 after acquiring an additional 702,030 shares during the last quarter. Farallon Capital Management LLC lifted its stake in shares of Voyager Therapeutics by 77.4% during the first quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company’s stock valued at $21,339,000 after acquiring an additional 1,000,000 shares during the period. Great Point Partners LLC bought a new position in Voyager Therapeutics in the second quarter valued at about $12,668,000. Finally, Geode Capital Management LLC increased its position in Voyager Therapeutics by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock worth $6,316,000 after purchasing an additional 6,740 shares during the period. 48.03% of the stock is currently owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.